Evaluating the Potential for Hepatitis B Virus Reactivation in COVID-19 Patients Undergoing Corticosteroid Therapy: A Retrospective Observational Study - Takeaways - MDSpire

Evaluating the Potential for Hepatitis B Virus Reactivation in COVID-19 Patients Undergoing Corticosteroid Therapy: A Retrospective Observational Study

  • By

  • Daša Stupica

  • Stefan Collinet-Adler

  • Janina Jerman Grašič

  • Deja Juriševič

  • Nataša Kejžar

  • Mario Poljak

  • Tina Štamol

  • January 20, 2026

  • 0 min

Share

  • 1

    Systemic corticosteroids are recommended for hospitalized COVID-19 patients, but they may increase the risk of hepatitis B virus reactivation.

  • 2

    The risk of HBV reactivation is substantial in anti-HBc positive patients receiving high-dose corticosteroids for extended periods.

  • 3

    EASL guidelines suggest antiviral therapy for patients with HBV during corticosteroid treatment for COVID-19 to prevent reactivation.

  • 4

    This study evaluates adherence to HBV screening guidelines in a low-prevalence country and assesses HBV reactivation risk.

  • 5

    Understanding HBV management during corticosteroid therapy for COVID-19 is crucial for patient safety and effective treatment.

Original Source(s)

Evaluating the Potential for Hepatitis B Virus Reactivation in COVID-19 Patients Undergoing Corticosteroid Therapy: A Retrospective Observational Study

  • by Daša Stupica, Stefan Collinet-Adler, Janina Jerman Grašič, Deja Juriševič, Nataša Kejžar, Mario Poljak, Tina Štamol

  • January 20, 2026

Related Content

Disparate SARS-CoV-2 Infection Outcomes Abound, but What Makes SARS-CoV-2 Bound for Rebound?

Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.